{"id":462,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"survodutide-synchronize-1-2026-phase-3-data","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/survodutide-synchronize-1-2026-phase-3-data\/","title":{"rendered":"Survodutide em SYNCHRONIZE-1: Os n\u00fameros 2026 da fase 3 no contexto"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">SYNCHRONIZE-1 \u00e9 o maior estudo publicado sobre obesidade com survodutida at\u00e9 o momento. A evid\u00eancia \u00fatil est\u00e1 no denominador completo, na estimativa, na resposta ao placebo e no padr\u00e3o de eventos adversos \u2013 e n\u00e3o numa \u00fanica percentagem do t\u00edtulo.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">O que o registro mostra<\/h2><ul class=\"wp-block-list\"><li>O estudo randomizou adultos 725 com obesidade sem diabetes.<\/li><li>Na semana 76, a altera\u00e7\u00e3o m\u00e9dia do peso foi \u221212.2% e \u221213.0% nos dois grupos de survodutida versus \u22125.4% com placebo.<\/li><li>Eventos adversos gastrointestinais ocorreram em 80.9% e 89.7% de participantes de survodutida versus 47.9% com placebo.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png\" alt=\"Cientista revisando dados de ensaios metab\u00f3licos e duas vias de sinaliza\u00e7\u00e3o de receptores\" class=\"wp-image-457\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Ilustra\u00e7\u00e3o editorial original do contexto da pesquisa. N\u00e3o \u00e9 uma figura de estudo, imagem do paciente, fotografia do produto fornecido ou representa\u00e7\u00e3o de material de estudo.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Registro de estudo<\/h2><p class=\"wp-block-paragraph\">A estimativa do regime de tratamento relatou altera\u00e7\u00f5es m\u00e9dias de \u221212.2% (95% CI, \u221213.6 a \u221210.8) e \u221213.0% (95% CI, \u221214.4 a \u221211.6), em compara\u00e7\u00e3o com \u22125.4% (95% CI, \u22126.9 a \u22124.0) para placebo. Ambas as compara\u00e7\u00f5es ativas foram estatisticamente significativas.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Projeto<\/strong><span>Ensaio de fase 3 randomizado, duplo-cego e controlado por placebo<\/span><\/div><div class=\"pim-evidence-row\"><strong>Participantes<\/strong><span>725; m\u00e9dia de idade 47.1 anos; significa BMI 37.9<\/span><\/div><div class=\"pim-evidence-row\"><strong>Resultado da semana-76<\/strong><span>\u221212.2%, \u221213.0% e \u22125.4% significam mudan\u00e7a de peso<\/span><\/div><div class=\"pim-evidence-row\"><strong>Pelo menos redu\u00e7\u00e3o de 5%<\/strong><span>72.6%, 71.9% e 46.3%<\/span><\/div><div class=\"pim-evidence-row\"><strong>Mortes<\/strong><span>Nenhum relatado no ensaio publicado<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Resultados no contexto<\/h2><p class=\"wp-block-paragraph\">O endpoint de resposta \u22655% aponta na mesma dire\u00e7\u00e3o, mas o grupo placebo tamb\u00e9m teve uma resposta substancial. Isso \u00e9 importante porque todos os grupos participaram de um ensaio controlado, em vez de uma compara\u00e7\u00e3o sem interven\u00e7\u00e3o.<\/p><p class=\"wp-block-paragraph\">O jornal chama a survodutide investigacional. N\u00e3o estabelece intercambialidade entre a formula\u00e7\u00e3o experimental e um material de cat\u00e1logo de origem independente.<\/p><h2 class=\"wp-block-heading\">O que este estudo n\u00e3o pode responder<\/h2><p class=\"wp-block-paragraph\">Os participantes n\u00e3o tinham diabetes, portanto o resultado n\u00e3o deve ser generalizado para todas as popula\u00e7\u00f5es metab\u00f3licas.<\/p><p class=\"wp-block-paragraph\">O artigo 3 de uma fase n\u00e3o pode responder perguntas sobre uso p\u00f3s-aprova\u00e7\u00e3o de longo prazo, eventos raros ou um lote de pesquisa n\u00e3o relacionado.<\/p>","protected":false},"excerpt":{"rendered":"<p>SYNCHRONIZE-1 \u00e9 o maior estudo publicado sobre obesidade com survodutida at\u00e9 o momento. A evid\u00eancia \u00fatil est\u00e1 no denominador completo, na estimativa, na resposta ao placebo e no padr\u00e3o de eventos adversos \u2013 e n\u00e3o numa \u00fanica percentagem do t\u00edtulo.<\/p>","protected":false},"author":1,"featured_media":627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"365","pim_article_type":"Published study case","pim_evidence_level":"Randomized phase 3 human trial; investigational intervention","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Survodutide Once Weekly for Adults with Obesity \u2014 SYNCHRONIZE-1\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42253238\/\",\"note\":\"2026 phase 3 primary record; PMID 42253238.\"},{\"title\":\"Survodutide phase 2 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38330987\/\",\"note\":\"Dose-ranging clinical context; PMID 38330987.\"},{\"title\":\"ClinicalTrials.gov NCT06066515\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT06066515\",\"note\":\"Registry record for SYNCHRONIZE-1.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD<\/title>\n<meta name=\"description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/survodutide-synchronize-1-2026-phase-3-data\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\" \/>\n<meta property=\"og:description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/survodutide-synchronize-1-2026-phase-3-data\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Survodutide em SYNCHRONIZE-1: Os n\u00fameros 2026 da fase 3 no contexto - NHD","description":"SYNCHRONIZE-1 \u00e9 o maior estudo publicado sobre obesidade com survodutida at\u00e9 o momento. A evid\u00eancia \u00fatil est\u00e1 no denominador completo, na estimativa, na resposta ao placebo e\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/survodutide-synchronize-1-2026-phase-3-data\/","og_locale":"pt_BR","og_type":"article","og_title":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","og_description":"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026","og_url":"https:\/\/nhdbio.com\/pt-br\/survodutide-synchronize-1-2026-phase-3-data\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","url":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","name":"Survodutide em SYNCHRONIZE-1: Os n\u00fameros 2026 da fase 3 no contexto - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"SYNCHRONIZE-1 \u00e9 o maior estudo publicado sobre obesidade com survodutida at\u00e9 o momento. A evid\u00eancia \u00fatil est\u00e1 no denominador completo, na estimativa, na resposta ao placebo e\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=462"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/462\/revisions"}],"predecessor-version":[{"id":514,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/462\/revisions\/514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/627"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}